
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE
ACT OF 1934**

May 7, 2018

Commission File Number: **001-36686**

Forward Pharma A/S

**Østergade 24A, 1st Floor
1100 Copenhagen K, Denmark**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes ☐ No ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes ☐ No ☒

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

Item 1. Company Presentation

On May 7, 2018, Forward Pharma A/S (the “Company”) made available an updated investor presentation on its website. A copy of the investor presentation is attached hereto as Exhibit 99.1.

The fact that this presentation is being made available and filed herewith should not be deemed an admission as to the materiality of any information contained in the materials. The information contained in the presentation is being provided as of May 7, 2018 and the Company does not undertake any obligation to update the presentation in the future or to update forward-looking statements to reflect subsequent actual results.

Item 2. Issuance of Press Release

On May 7, 2018, the Company issued a press release announcing the filing of a notice of appeal of the decision of the Opposition Division of the European Patent Office that revoked EP2801355, a copy of which is attached hereto as Exhibit 99.2.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Forward Pharma A/S

Date: May 7, 2018

By: /s/ Claus Bo Svendsen
Name: Claus Bo Svendsen
Title: Chief Executive Officer

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
<u>99.1</u>	<u>Investor Presentation dated May 7, 2018</u>
<u>99.2</u>	<u>Press Release dated May 7, 2018</u>



Forward Pharma (*Nasdaq:FWP*) Corporate Update

May 7, 2018




Claus Bo Svendsen, MD, PhD
Chief Executive Officer

2018© Forward Pharma A/S

Certain statements in this presentation may constitute “forward-looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements which contain language such as “believe”, “expect”, “anticipate”, “estimate”, “would”, “may”, “plan” and “potential”. Forward-looking statements are predictions only, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, risks related to the following: the satisfaction of certain conditions, and the accuracy of certain representations of the Company, in the Settlement and License Agreement entered into with subsidiaries of Biogen Inc. and certain other parties thereto; our ability to obtain, maintain, enforce and defend issued patents with royalty-bearing claims; our ability to prevail in the interference proceeding after all appeals and obtain issuance of the '871 application; our ability to prevail in or obtain a favorable decision in the '355 European Opposition Proceedings, after all appeals; the expected timing for key activities and an ultimate ruling in such legal proceedings; the issuance and term of our patents; future sales of Tecfidera®, including impact on such sales from competition, generic challenges, regulatory involvement and pricing pressures; the scope, validity and enforceability of our intellectual property rights in general and the impact on us of patents and other intellectual property rights of third parties; and our ability to generate revenue from product sales in the U.S. directly or through an assignee of our U.S. co-exclusive license rights in the event Biogen does not obtain an exclusive license from us in the U.S. Certain of these and other risk factors are identified and described in detail in certain of our filings with the United States Securities and Exchange Commission, including our Annual Report on Form 20-F for the year ended December 31, 2017. We are providing this information as of the date of this presentation and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise.


- Tecfidera® (DMF) remains a leading therapy for multiple sclerosis
 - Global sales: 2017 (\$ 4.2 B); 2022 (forecast to \$4.46 B)
 - US sales ~80%; ex-US sales ~20%
- FWP has IP-gated access to future royalties on Tecfidera® sales
 - Irrevocable license to all DMF IP granted to Biogen in January 2017
 - Potential future royalties on Tecfidera® sales dependent on
 - *in US*: upcoming legal decision expected in 2018
 - *outside US*: outcome of appeal of Opposition Division decision
- Business optimized to support ongoing IP strategy and continuing obligations per settlement & license agreement
- Capital reduction and shareholder distribution of EUR 917.7 M effected September 2017

Share Value Drivers under the Settlement and License Agreement




1. Analyst consensus estimates, EvaluatePharma, May 2017. Not meant to be comprehensive; size of boxes is arbitrary and not meant to illustrate comparative differences in amounts. Appropriate risk-adjustment should be applied. Potential investors and current shareholders are strongly urged to read the Settlement and License Agreement in its entirety as well as our Annual Report on Form 20-F for the year ended December 31, 2017, where risk factors are identified and described in detail.

Timeline for IP litigation in U.S.




Dates represent current estimates of the timeline; a green tick mark signifies actual date of completed event.
Documents for the US appeal can be located through <https://ecf.cafc.uscourts.gov/>


Timeline for the appeal of the first instance decision in the EP'355 Opposition Proceedings



Dates represent current estimates of the timeline; a green tick mark signifies actual date of completed event.
Documents can be located through <https://register.epo.org/regviewer>



Adapted from Coles A, Newer therapies for multiple sclerosis. Ann Indian Acad Neurol 2015;18, Suppl S1:30-4



Regulatory Data Exclusivity and Patent Protection


- Settlement and License Agreement adds Forward Pharma IP

Launch of Ocrevus®

- Based on analyst reports and interviews with EU and US KOLs, Ocrevus® is converting later stage patients on injectables and adding a Progressive MS market


Potential Generic Fingolimod and additional S1P modulators

Gating Events for Royalties on Tecfidera® Sales



The summary of the Settlement and License Agreement in this presentation does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Settlement and License Agreement, which is available on Forward's website. Potential investors and current shareholders are strongly urged to read the Settlement and License Agreement in its entirety as well as our Annual Report on Form 20-F for the year ended December 31, 2017.

Potential Royalty Rates on Tecfidera® Net Sales



(a) Subject to, among other things, expiration or invalidation of the patents or impact of generic entry on a country-by-country basis, as defined in the License Agreement

(b) Royalties payable on a country-by-country basis on DMF-containing products indicated for MS that, but for the License Agreement, would infringe a Forward licensed patent

- **Interference declared April 13, 2015**

A patent interference is an administrative proceeding at the Patent and Trial Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) used to determine which party is the first to invent a common invention claimed by both parties.

- **Forward awarded “Senior Party” status**

The Senior Party has the earliest effective filing date to the common invention; entitled to the presumption that it is the first inventor.

- **On March 31, 2017, the USPTO PTAB ruled in favor of Biogen**

Without addressing which party was the first to invent the common invention claimed by both parties, the PTAB concluded that the Forward patent application did not have sufficient written description support for the claimed invention.

- **Forward is appealing the ruling to the U.S. Court of Appeals for the Federal Circuit**

Specialist team led by Kathleen Sullivan from Quinn Emanuel Urquhart & Sullivan, LLP.

Forward Pharma Reply Brief filed December 21, 2017. Oral argument scheduled on June 4, 2018.

Should the Forward appeal be successful, the interference will be returned to the USPTO to resume the interference proceedings. After completion of the interference proceedings, a further appeal to the U.S. Court of Appeals is possible.

- EP2801355 patent granted by European Patent Office (EPO) on May 20, 2015
- Subject to several oppositions filed with the EPO by third parties (including Biogen)
- **On January 29, 2018, the Opposition Division of the EPO revoked the EP'355 patent**
On March 22, 2018, the Opposition Division issued its reasoned written decision.
Appeal of the decision of the Opposition Division to the Technical Board of Appeal initiated on May 7, 2018, with expected conclusion in an additional 2-3 years.

Capital Reduction Executed in September 2017

- Decision was based on a careful evaluation of the most appropriate capital allocation strategy after receipt of the non-refundable \$ 1.25 billion cash fee from Biogen
- **EUR 917.7 M in total returned to shareholders**
- The capital reduction was the final step of the organizational transformation to align the amount of working capital with the adjusted business activities following the Settlement and License Agreement with Biogen.



Balance Sheet and Operating Results

Current per December 31, 2017



- Capital Reduction completed in September 2017
 - EUR 917.7 M distributed to shareholders
 - Current number of issued shares is 94,367,998, of which 24.34% are listed as American Depositary Shares (ADS) on Nasdaq (1 ADS represents 2 shares)
- Share information (*Nasdaq: FWP*; per May 4, 2018)
 - Closing price per ADS: \$ 2.27
 - Market Cap: \$ 107.1 M


Balance Sheet

	At December 31, 2017 USD '000s
Cash	\$ 109,554
Other assets	1,454
Total assets	111,008
Total shareholder equity	89,680
Total liabilities	21,328
Total shareholder equity and liabilities	\$ 111,008

Operating Results

	Year ended December 31, 2017 USD '000s
Revenue	\$ 1,250,000
Operating expenses	(62,603)
Other expenses (net)	(2,909)
Income tax expense	(267,395)
Net income	\$ 917,093

Share Value Drivers under the Settlement and License Agreement



1. Analyst consensus estimates, EvaluatePharma, May 2017. Not meant to be comprehensive; size of boxes is arbitrary and not meant to illustrate comparative differences in amounts. Appropriate risk-adjustment should be applied. Potential investors and current shareholders are strongly urged to read the Settlement and License Agreement in its entirety as well as our Annual Report on Form 20-F for the year ended December 31, 2017, where risk factors are identified and described in detail.

- **Upcoming qualifiers for future royalty from Tecfidera® sales**
 - **Appeal of U.S. PTAB interference decision to Federal Circuit**
 - Scheduled Oral Argument – June 4, 2018
 - **Expected Decision – Q3/4 2018**
- **European EP'355 Opposition Proceedings**
 - Appeal initiated – May 7, 2018
 - **Filing of grounds of appeal – due by August 2, 2018**

Claus Bo Svendsen, MD, PhD
Chief Executive Officer

Forward Pharma Investor Relations
investors@forward-pharma.com



4 patent applications are currently pending that, if issued, may contain claims that may be royalty-bearing if Forward obtains a Relevant Patent after all appeals in the Interference Proceeding

	Application Number	Description
US	11/576,871	Treating MS with DMF at 480 mg/day Interference declared; FWP as Senior Party – April 13, 2015 PTAB ruled in favor of Biogen – March 31, 2017 Appeal to the Federal Circuit fully briefed; oral argument – June 4, 2018
	15/834,870	Filed on December 7, 2017 Application pending (published), not yet examined
	14/212,503	Treating MS with DMF at 480 mg/day to reach certain MMF levels in the bloodstream On appeal from final rejection
	15/728,872	Claims to a pharmaceutical composition comprising DMF in an amount of 50-90% by weight to be filed

A Relevant Patent is a patent that covers treatment for MS by orally administering 480 mg per day of DMF.

If we prevail in the Interference Proceeding after any appeals to the Federal Circuit, we further expect the 11/576,871 application, if ultimately issued, would be entitled to patent term adjustment that would result in an estimated patent expiration in 2029 or later. There is no assurance that patent term adjustment would be obtained to fully compensate for all such time lost.

If Forward obtains a Relevant Patent in the European EP'355 opposition proceedings including all appeals therefrom, and can show on a country-by-country basis that Tecfidera® infringes a valid licensed patent, royalties may be payable. In Europe, there are presently four patents and patent applications with potentially royalty-bearing claims.

	Application Number	Description
Ex-US	EP14172398.1 (Pat. No. EP2801355)	Treating MS with 480 mg/day of DMF wherein the pH controlled release compositions have an enteric coat Revoked by Opposition Division – January 29, 2018 Appeal filed – May 7, 2018
	EP15166243.4 (Pat. No. EP2965751)	Treating MS with 480-600 mg fumaric acid esters (including DMF)/day where the composition releases fumaric acid esters depending on pH. Application pending
	EP14172396.5 (Pat. No. EP2792349)	Controlled release composition of DMF for use in treating hyperproliferative, inflammatory or autoimmune disorders other than psoriasis with 480 mg/day Application pending
	EP16001391.8 (Pat. No. EP3093012)	Controlled release pharmaceutical composition comprising DMF in an amount of 50-90% by weight Application pending

A Relevant Patent is a patent that covers treatment for MS by orally administering 480 mg per day of DMF.

Key IP Overview:

Core Composition and Erosion Matrix Patent Families¹



Patent / Application	Patent Family	Status
U.S. App. 11/576,871	Core Composition	Pending and involved in an interference proceeding. A decision was issued by the PTAB on March 31, 2017 in favor of Biogen. Currently under appeal with the Federal Circuit.
U.S. App. 15/834,870	Core Composition	Pending.
U.S. App. 14/212,503	Core Composition	On appeal from final rejection.
U.S. App. 15/728,872	Core Composition	Pending.
EP2801355	Core Composition	Revoked by decision of January 29, 2018; under appeal.
EP1799196	Core Composition	Granted. Under opposition with EPO.
EP2801354	Core Composition	Granted. Under opposition with EPO.
EP3093012	Core Composition	Pending. Further processing.
EP2965751	Core Composition	Pending.
EP2792349	Core Composition	Pending. Further processing.
U.S. Patent No. 8,906,420	Erosion Matrix	Granted.
U.S. App. 15/945,005	Erosion Matrix	Pending.
EP2379063	Erosion Matrix	Granted; opposition rejected; appeal pending.
EP2564839	Erosion Matrix	Granted. Under opposition with EPO.
EP3295936	Erosion Matrix	Pending.
JP5788331	Erosion Matrix	Granted as JP2012-514624.

1. Beyond the core composition patent and erosion matrix patent families, other patent families include U.S. Patent Application Nos. 15/834,799, 15/723,749 and European Patent Application Nos. EP2879672, EP3038606 and EP3038605. As a result of the corporate restructuring that was completed pursuant to Appendix D of the Settlement and License Agreement, the intellectual property of Forward Pharma that is the subject of the Settlement and License Agreement was ultimately transferred to FWP IP ApS, a Danish limited liability company, and the capital stock of FWP IP ApS was transferred to a newly formed independent Danish foundation. For more information regarding this restructuring and transfer, see our Form 6-K and press release dated November 22, 2017.

Date of preparation: May 7, 2018

Forward Pharma Appeals the Decision of the Opposition Division to Revoke the EP2801355 Patent

COPENHAGEN, Denmark, May 07, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (“We” or “Forward” or the “Company”), today announced the filing of a notice of appeal of the decision of the Opposition Division of the European Patent Office (the “EPO”) that revoked EP2801355 (the “’355 patent”), written reasons for which were received on March 22, 2018. The notice was filed to the Technical Board of Appeal (the “TBA”) of the EPO.

“With the notice of appeal filed, we officially initiate the process to get the decision of the Opposition Division overturned and have the ‘355 patent reinstated,” said Dr. Claus Bo Svendsen, Chief Executive Officer of Forward.

On January 29, 2018, the Opposition Division of the EPO heard the oral proceedings concerning the validity of the ‘355 patent and issued an oral decision revoking the ‘355 patent after considering third-party oppositions from several opponents. On March 22, 2018, the Opposition Division issued its written decision with detailed reasons for the decision, and following a thorough review of these, the Company has now decided to appeal the Opposition Division’s decision to the TBA. The appeal process has an expected duration of an additional two to three years. The Company has until August 2, 2018 to submit its detailed grounds of appeal. By initiating the appeal, the revocation will only become effective if and when confirmed by the TBA. If the Company prevails in such appeal, we expect the TBA to remand the case to the Opposition Division, for the Opposition Division to resolve the remaining elements of the original opposition.

About Forward Pharma:

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187[®], a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the recent Settlement and License Agreement and received from Biogen a non-refundable cash fee of \$1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera[®] or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 Opposition Proceedings, including any appeal thereto.

Publicly available information from the European Patent Office can be located at the European Patent Register at <https://register.epo.org/regviewer>.

The principal executive offices are located at Østergade 24A, 1st Floor, 1100 Copenhagen K, Denmark and our American Depositary Shares are publicly traded on Nasdaq Stock Market (FWP). For more information about the Company, please visit our website at <http://www.forward-pharma.com>.

Forward Pharma A/S Investor Relations Contact:

Forward Pharma A/S
Dr. Claus Bo Svendsen, Chief Executive Officer
Investor Relations
investors@forward-pharma.com

The Trout Group
John Graziano
jgraziano@troutgroup.com
+1 (646) 378 2942

Forward Looking Statements:

Certain statements in this press release may constitute “forward-looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements which contain language such as “believe,” “expect,” “anticipate,” “estimate,” “would,” “may,” “plan,” and “potential.” Forward-looking statements are predictions only, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, risks related to the following: the satisfaction of certain conditions, and the accuracy of certain representations of the Company, in the Settlement and License Agreement entered into with subsidiaries of Biogen Inc. and certain other parties thereto; our ability to obtain, maintain, enforce and defend issued patents with royalty-bearing claims; our ability to prevail in the interference proceedings after all appeals and obtain issuance of the ‘871 application; our ability to prevail in or obtain a favorable decision in the ‘355 patent European Opposition Proceedings, after all appeals; the expected timing for key activities and an ultimate ruling in such legal proceedings; the issuance and term of our patents; future sales of Tecfidera[®], including impact on such sales from competition, generic challenges, regulatory involvement and pricing pressures; the scope, validity and enforceability of our intellectual property rights in general and the impact on us of patents and other intellectual property rights of third parties; and our ability to generate revenue from product sales in the U.S. directly or through an assignee of our U.S. co-exclusive license rights in the event Biogen does not obtain an exclusive license from us in the U.S. Certain of these and other risk factors are identified and described in detail in certain of our filings with the United States Securities and Exchange Commission, including our Annual Report on Form 20-F for the year ended December 31, 2017. We are providing this information as of the date of this release and do not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.